• Intensity Therapeutics

  Participated · Series A · Jun 2016

  Intensity Therapeutics is a clinical-stage biotech leveraging its DfuseRxSM platform to create intratumoral formulations that disperse therapeutic agents throughout tumors and induce adaptive immune responses. Its lead product candidate, INT230-6, is a direct intratumoral injection comprised of two anti-cancer agents plus a penetration enhancer designed to diffuse into cancer cells. INT230-6 is being evaluated in an ongoing Phase 1/2 clinical study (NCT03058289) in patients with advanced solid tumors, with preliminary data showing the drug was well tolerated, with no drug-related serious adverse events or dose-limiting toxicities. Early signals included increases in circulating CD8 and CD4 T-cells and evidence of abscopal responses in non-injected tumors. The company plans to expand the study to sites outside the U.S. and Canada, add combination arms with an anti-PD-1 antibody, and initiate Phase 2a studies in specific tumor types. Proceeds from the recent financing are intended to support advancement of INT230-6 into Phase 2 clinical development. Intensity Therapeutics is developing proprietary cancer immunotherapy products built on its DfuseRx platform, focused on an in situ vaccination approach. Its lead candidate, INT230-6, is a novel product designed to disperse through tumors, kill cancer cells, and recruit immune cells to the tumor microenvironment. In preclinical in vivo models INT230-6 has cleared large tumors, improved overall survival versus standard therapies, and produced durable, vaccine-like protection against re‑exposure. The company plans to use new capital to manufacture clinical supplies, complete regulatory filings and run a series of clinical trial cohorts in cancer patients with various tumor types, including planned Phase I/II efforts. Management has emphasized rapid advancement from product concept to an IND-ready candidate and has strengthened its board with experienced drug developers to support upcoming human trials. The company is privately held and headquartered in Westport, Conn.

No current team members are available.